Article citationsMore>>

Shao, W., Mischina, Y., Caponigro, G., Ramurthy, S., Cooke, V., Griner, L., Nishiguchi, G., Rico, A., Taft, B., Burger, M., Tanner, H., Polyakov, V., Appleton, B., Tellew, J., Zang, R., Amiri, P., Singh, M. and Stuart, D. (2016) Development of a Highly Selective B/CRAF Kinase Inhibitor That Exhibits Antitumour Activities in Ras and BRAF Mutation. American Journal of Cancer, 16, 242-258.

has been cited by the following article:

• TITLE: Role of Tyrosine Kinase Receptors in Growth Factor Mediated Signal Transduction, with Specific Reference to MAPK/Rasand p13k-Akt Containing Pathways in Oncogenesis: A Qualitative Database Review

  AUTHORS: Chanjugaa Uthayakumar, Rajavarthani Sanjeev

  KEYWORDS: Receptor Tyrosine Kinase, PI3/AKT, MAP Kinase, PTEN, Cancer, Receptor Inhibitor

  JOURNAL NAME: American Journal of Molecular Biology, Vol.12 No.4, August 18, 2022

  ABSTRACT: Receptor Tyrosine kinases (RTKs) play a crucial role in the signal transduction pathways at cellular levels. RTK plays a vital role in cellular communication and transmission of signals to the adjacent cells and regulates different functions of the cell, such as cellular growth, differentiation, metabolism and motility. RTK s triggers growth factor receptors such as epidermal growth factor, insulin growth factor-1 receptor, platelet derived growth factor receptor, and fibro blast growth factor receptor and vascular endothelial growth factor receptor, thereby initiating and regulating cell growth and proliferation. MAPK/RAS and PI3/AKT pathways are the major pathways of RTK’s function. Dysregulation of these RTK’s and pathways often leads to many diseases such as Noonan Syndrome, Logius Syndrome, CFC syndrome and different types of cancer. Point mutation and over expression of receptors and mutations in Ras leads to 30% of human cancers. Also over expression of different growth factor receptors by RTK too lead to several types of cancers as Glioblastoma, Thyroid cancer, Colon cancer and Non-small cell lung cancer. PTEN mutation in PI3/AKT pathway often leads to carcinoma relative to Thyroid, Skin, Large intestine, eye and Bone. Therefore, these RTK’s often used as targets for cancer therapies. The medical sector uses various types of small molecule tyrosine kinase inhibitors such as ATP competitive inhibitors, Allosteric inhibitors and covalent inhibitors which are known as Afatinib, Crizotinib, Eroltinib, Icotinib, Lepatinib and Lenvatinib in treatment and management of differential carcinomas.